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Abnormal iron metabolism is observed in many neurodegenerative diseases, however,
only two have shown dysregulation of brain iron homeostasis as the primary cause of
neurodegeneration. Herein, we review one of these - hereditary ferritinopathy (HF) or
neuroferritinopathy, which is an autosomal dominant, adult onset degenerative disease
caused by mutations in the ferritin light chain (FTL) gene. HF has a clinical phenotype
characterized by a progressive movement disorder, behavioral disturbances, and cognitive
impairment. The main pathologic findings are cystic cavitation of the basal ganglia, the
presence of ferritin inclusion bodies (IBs), and substantial iron deposition. Mutant FTL
subunits have altered sequence and length but assemble into soluble 24-mers that are
ultrastructurally indistinguishable from those of the wild type. Crystallography shows
substantial localized disruption of the normally tiny 4-fold pores between the ferritin
subunits because of unraveling of the C-termini into multiple polypeptide conformations.
This structural alteration causes attenuated net iron incorporation leading to cellular iron
mishandling, ferritin aggregation, and oxidative damage at physiological concentrations of
iron and ascorbate. A transgenic murine model parallels several features of HF, including
a progressive neurological phenotype, ferritin IB formation, and misregulation of iron
metabolism. These studies provide a working hypothesis for the pathogenesis of HF
by implicating (1) a loss of normal ferritin function that triggers iron accumulation and
overproduction of ferritin polypeptides, and (2) a gain of toxic function through radical
production, ferritin aggregation, and oxidative stress. Importantly, the finding that ferritin
aggregation can be reversed by iron chelators and oxidative damage can be inhibited by
radical trapping may be used for clinical investigation. This work provides new insights into
the role of abnormal iron metabolism in neurodegeneration.
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INTRODUCTION
Hereditary ferritinopathy (HF) or neuroferritinopathy is an auto-
somal dominant, adult onset neurodegenerative disease caused by
mutations in the ferritin light chain (FTL) gene (Curtis et al.,
2001; Vidal et al., 2004a; Mancuso et al., 2005; Ohta et al.,
2008; Devos et al., 2009; Kubota et al., 2009). The disease was
first reported in members of two families from England and
France and was named neuroferritinopathy (Curtis et al., 2001).
Sequence analysis of the FTL gene in members of the English
family disclosed an adenine duplication, which predicts alteration
of the C-terminal FTL polypeptide sequence and length (Curtis
et al., 2001). Thus, far, six different mutations in exon four of the
FTL gene have been reported, all affecting the FTL C-terminus.
The clinical phenotype of HF is characterized by a movement dis-
order, behavioral abnormalities, and cognitive impairment. The
brain shows cerebral and cerebellar atrophy and cavitation of the
putamen. The main neuropathologic findings are the presence of
intranuclear and intracytoplasmic ferritin inclusion bodies (IBs)
in glial cells and in some subsets of neurons, and abnormal iron
deposition. Molecular level investigations of ferritin containing
the mutant subunit reveal functional defects of iron mishandling,
ferritin aggregation, and oxidative damage. These processes are
linked to a structural defect in the FTL C-terminus leading to cel-
lular dysfunction that can be broadly classified as a loss of normal
function and gain of toxic function as discussed below.
FERRITIN STRUCTURE, IRON CHEMISTRY, AND PROTEIN
AGGREGATION
Ferritin is uniquely suited for its crucial iron sequestration
and storage function. Ferritin consists of 24 subunits that can
self-assemble into a 480 kDa hollow sphere of ∼110 Å outer
and ∼80Å inner diameter (Figures 1A, B), which can store up
to 4500 atoms of iron as a ferrihydrite biomineral (Vidal et al.,
2004b; Crichton and Declercq, 2010). The exterior and interior
of the ferritin shell are connected via channels (pores) along 3-
fold and 4-fold symmetry axes at subunit junctions. There are
eight 3-fold pores that are larger diameter and shorter relative
to the six 4-fold pores. The 3-fold pores (Figure 1C), which are
hydrophylic, have been implicated as the iron entry pathway in a
number of studies, whereas the 4-fold pores (Figure 1D), which
are hydrophobic, are smaller and considered essentially closed,
especially to ions. Human ferritin is usually heteropolymeric with
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FIGURE 1 | Structure of ferritin, one of its 24 subunits, and its pores.
Ferritin assembles spontaneously from 24 conformationally equivalent
subunits into a hollow spherical shell (A) with 2-, 3-, and 4-fold symmetry
axes. The subunits (B) are each composed of five α-helices with four of
them parallel and tightly associated and the fifth (the E-helix) at an angle
and pointed inwards. The junctions of the subunits form hydrophilic pores
at the 3-fold axes (C), which are implicated as the entry path for iron ions,
and hydrophobic pores at the 4-fold axes (D), which are smaller and
considered closed, especially to ions. Pores are viewed from the ferritin
shell interior with the inwardly pointing E-helices from the 4 subunits clearly
visible in (D). Structures were taken from RCSB (code 2FG8).
the 24-mer formed from two conformationally equivalent sub-
units with slightly different masses and 54% sequence identity.
The two subunits are folded from the ferritin heavy chain (FTH1)
and light chain (FTL) polypeptides with the former longer by
8 amino acids. Both subunits consist of four parallel α-helices
(A–D) of∼45Å length and a shorter, carboxy terminal α-helix (E)
at a 60◦ angle to the parallel helix bundle pointing into the inte-
rior of the shell (Figure 1B) (Crichton and Declercq, 2010). The
4-fold pores are formed from four hydrophobically-associated
E-helices donated from four different subunits (Figure 1D), while
3-fold pores are formed from C- and D-helices from three sub-
units (Figure 1C). The FTH1 subunit contains the ferroxidase site
in the interior of the parallel helix bundle, which converts Fe2+
to Fe3+ in the presence of O2 on the pathway to biomineraliza-
tion. Iron then migrates to the ferrihydrite nucleation site on the
interior surface of the FTL subunit to complete biomineral forma-
tion. Interestingly, each organ fine tunes the ratio of FTH1 to FTL
subunits, which can vary substantially, for optimal physiologi-
cal function. No homopolymers of the FTH1 subunit have been
reported, but homopolymeric ferritin formed from 24 FTL sub-
units is capable of a slow rate of iron sequestration and storage.
The FTL subunit is more stable than the FTH1 subunit toward
increasing temperature and denaturants, and when incorporated
into the heteropolymer stabilizes it and hinders iron-induced
aggregation (Santambrogio et al., 1992, 1993).
Properly functioning ferritin of the appropriate cellular con-
centration is essential for iron homeostasis, and a number of
neurodegenerative diseases have links with misregulation of iron
(Zecca et al., 2004; Berg and Youdim, 2006). The normal cellular
response to abundant iron is to decrease the synthesis of the
transferrin receptor, which transports iron into the cells, and
to increase ferritin synthesis for appropriate iron sequestration
and storage. During iron deficiency the synthesis of ferritin is
inhibited in part by an increase in Iron Responsive Protein (IRP)
binding to the Iron Responsive element (IRE) on target mRNAs.
Clearly, ironmust be made available to form the essential catalytic
centers of neuroenzymes, e.g., tryptophan hydroxylase, which is
required for serotonin synthesis, and tyrosine hydroxylase leading
to dopamine. However, local iron concentration and its ligation
(coordination) and oxidation state must all be carefully reg-
ulated to prevent cellular damage. Indeed, the chemistry that
occurs at the iron can vary substantially depending on iron lig-
ation, which could be provided by protein donors (e.g., certain
amino acid side chains) or small molecules normally available in
cells. Much cellular chemistry is driven by the process of redox
change, and cells have available the redox drivers of reductants
such as NADPH, glutathione, and ascorbate, as well as oxygen.
Hydrogen peroxide and superoxide are generated in cells as part
of several routine metabolic redox processes as well as by non-
enzymatic reduced iron, and although they can deactivate a few
enzymes, they are not particularly damaging at appropriate lev-
els (Zecca et al., 2004). In fact, hydrogen peroxide has recently
been characterized as a neuromodulator in striatal dopamine
release (Rice, 2011). However, improperly coordinated iron has
the potential to convert hydrogen peroxide and superoxide into
the highly toxic hydroxyl radical, which is extraordinarily reac-
tive. This radical indiscriminately attacks proteins, lipids, and
DNA causing protein oxidation, fragmentation, and covalent
crosslinking leading to their loss of function. Hydroxyl radi-
cal production occurs through redox change in metal-centered
Fenton- and Haber-Weiss- type reactions, and when iron is coor-
dinated by less than 6 strongly-bound ligands this conversion is
facilitated (Graf et al., 1984). Hydrogen peroxide, superoxide, and
the hydroxyl radical are generally termed reactive oxygen species
(ROS), and cells produce enzymes (e.g., glutathione peroxidase,
catalase, and superoxide dismutase) and small molecules (glu-
tathione) to help control their levels (Murphy et al., 2011). The
ability of ferritin to convert Fe2+ to Fe3+ and store it internally
as a non-reactive biomineral can be considered a “detoxification”
function by removing it from potentially inappropriate ligation
and reactions. Although usually considered as antioxidants, glu-
tathione and ascorbate have concentrations in the brain that are
sufficiently high enough to provide reducing equivalents that can
generate ROS and thus lead to cellular damage in the presence of
improperly coordinated iron. Along these lines, during iron excess
the likelihood of inappropriate iron coordination by normally
available small molecule cellular constituents, which are not part
of proteins and usually not problematic, is increased potentially
causing the generation of ROS beyond basal levels and protein
oxidation.
Proper disposal or reconstitution of damaged or misfolded
proteins to avoid aggregation is an ongoing necessary cellu-
lar function, and protein aggregation is strongly linked with
neurodegenerative diseases (Lansbury and Lashuel, 2006). Cells
devote significant resources energetically through specialized
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protein synthesis and transport toward the disposal or reconstitu-
tion of oxidized or misfolded proteins, which are generally prone
to aggregate formation. The aggregation process is dependent
upon a variety of factors besides the identity and extent of abnor-
mality of the primary protein involved such as its concentration,
cellular crowding by other proteins, and the presence of small
molecules and metal ions. However, the aggregation process is
generally thought to follow one of two paths. The misfolded pro-
tein first forms dimers, trimers, and oligomers with a structural
rearrangement, and then forms highly ordered and symmet-
ric structures, e.g., fibrils in Alzheimer disease. Alternately the
aggregation process may involve less ordered clumping or pack-
ing together of proteins that leads to various tangles or IBs.
Often the most toxic forms are the smaller oligomers and poorly
ordered aggregates, and there is substantial evidence for this
with the larger structures considered neuroprotective. However,
the larger, microscopically visible IBs may not be inert cel-
lular end products, but influence metabolism, transport and
structure, perhaps even through causing detrimental mechanical
crowding.
Transition metal ions such as iron, copper and zinc are often
found at elevated levels in neurodegenerative diseases and are
intimately connected with protein aggregation, misfolding and
cellular dysfunction (Ayton et al., 2012). For example, the addi-
tion of iron to solutions of α-synuclein or amyloid β enhances
the rate of aggregation and/or fibril formation even to the extent
of influencing the structure of the aggregates formed, and ele-
vated iron is associated with the pathology of these disorders in
both animal models and humans. Metal ion binding can be causal
to aggregation and misfolding, or be advantageous after they
occur. However, metal ion-induced aggregated and misfolded
proteins, while problematic for cellular processes and elimination,
could foster an additional cellular dysfunction through provid-
ing binding sites that improperly ligate (coordinate) iron and
thus generate ROS. The resulting oxidative damage itself can
enhance protein aggregation. In Huntington disease IBs form
iron-dependent centers of oxidative damage causing alterations
in the cellular morphology of their surroundings (Firdaus et al.,
2006). Cells devote resources to respond to damaged or aggre-
gated proteins by synthesis of enzymes to repair or degrade
them. As will be discussed below, mutant ferritin is intimately
associated with iron mishandling, aggregation, and radical dam-
age of proteins, which can be traced directly to a protein structural
abnormality resulting from its disordered C-terminal helices and
unstructured 4-fold pores (Baraibar et al., 2010).
CLINICAL PRESENTATION, GENETICS, AND PATHOLOGY
OF HF
The neurodegenerative disease HF has been reported in members
of Caucasian and Japanese families, being inherited in an autoso-
mal dominant pattern. Linkage analysis, performed on members
of an English family, linked the disease to a locus on chromosome
19q13.3, which contains the FTL gene. Affected individuals from
this family were found to have an adenine insertion at position
460–461 of the FTL gene (c.460dupA) that was predicted to alter
the carboxyl-terminal region of the protein (Curtis et al., 2001).
Five additional mutations have been reported, all in exon 4 of the
FTL gene, which consists of 4 exons and 3 introns. In all cases, the
mutations (Table 1) affect the E-helix of the FTL polypeptide by
altering both the C-terminal sequence and extending its length.
In addition to these, two more cases of HF have been described.
The first case was diagnosed pathologically and no genetic data
is available (Schröder, 2005), while the second case was described
as an individual with a missense mutation (A96T) in FTL (Maciel
et al., 2005). In the later, it remains to be seen whether this case
reflects a bigger spectrum of the disease or a different condi-
tion since the mother of the proband (also a carrier of the A96T
mutation who displayed similar MRI findings) was asymptomatic
(lack of autosomal dominant transmission), and the patient did
not have significant involvement of the putamen, thalamus, and
substantia nigra.
Clinically, HF presents as a movement disorder syndrome sim-
ilar to Huntington disease or Parkinson disease. The disease may
present with tremor, cerebellar signs, Parkinsonism, psychiatric
problems, abnormal involuntary movements (dystonia, chorea),
pyramidal syndrome, pseudo-bulbar symptoms, and cognitive
deficit (Caparros-Lefebvre et al., 1997; Curtis et al., 2001; Vidal
et al., 2004a; Mancuso et al., 2005; Chinnery et al., 2007; McNeill
et al., 2008; Ohta et al., 2008; Devos et al., 2009; Kubota et al.,
2009; Ory-Magne et al., 2009). The clinical presentation of HF has
Table 1 | Sequence alignment of WT- and MT-FTL polypeptides starting at residue 142.
L I K K M G D H L T N L H R L G G P E A G L G E Y L F E R L T L K H D    
L I K K M G D H L T N L H K A G W P G G W A G R V S L R K A H S Q A R L R A F ………………………. 1
L I K K M G D H L T N L Q Q A G W P G G W A G R V S L R K A H S Q A R L R A F ………………………. 2
L I K K M G D R P P D Q P P Q A G W P G G W A G R V S L R K A H S Q A R L R A F …………………….. 3
L I K K M G D P P D Q P P Q A G W P G G W A G R V S L R K A H S Q A R L R A F ……………………….. 4
L I K K M G D H L T N L H R L G G P E A G R P G G W A G R V S L R K A H S Q A R L R A F …………… 5
L I K K M G D H L T N L H R L G G P E A G L G E Y L S S K G S L S S T T K S L L S P A T S E G P L A K 6
Wild-type
p.Arg154LysfsX27
p.His153GlufsX28
p.His148ArgfsX34
p.His148ProfsX33
p.Leu162ArgfsX24
p.Phe167SerfsX26
142 150 160 175
D E
Part of the helical domain D and the complete helical domain E of the WT-FTL subunit are shown above their respective sequences (Protein Data Bank code 2fg4).
MT-FTL polypeptides have a C-terminus that is altered in sequence and length. References are: (1) Curtis et al., 2001; (2) Devos et al., 2009; (3) Kubota et al., 2009;
(4) Mancuso et al., 2005; (5) Ohta et al., 2008; (6) Vidal et al., 2004a.
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been reported to differ both within and between families (Ory-
Magne et al., 2009), usually becoming evident in the third to fifth
decade of life (depending on the specific mutation) and progress-
ing unalleviated thereafter. Neuroimaging studies show abnormal
signals in the globus pallidus and putamen, and cavitation of
the putamen, while serum ferritin levels were reported to be
decreased in some patients (Curtis et al., 2001; Ory-Magne et al.,
2009). Neuropathological data is available for individuals with the
c.442dupC, c.460dupA, and c.497_498dupTC mutations (Curtis
et al., 2001; Vidal et al., 2004a; Mancuso et al., 2005). Examination
of the brain shows mild cerebral and cerebellar atrophy as well as
cavitations of the putamen. The main neuropathologic findings
(Figure 2) are the presence of intranuclear and intracytoplasmic
ferritin IBs in glial cells and in some subsets of neurons, substan-
tial iron deposition, and mild to moderate nerve cell loss and
gliosis. Glial cells containing IBs are mostly found in the cau-
date nucleus, putamen, and globus pallidus. These areas show
severe nerve cell loss, extracellular ferritin deposits, and loss of
neuropil. In the cerebral cortex, IBs are seen in perineuronal
cells and in perivascular glia. The presence of IBs in neurons
is clearly observed in the putamen, globus pallidus and thala-
mus, and in cerebellar granule cells and in Purkinje cells (Vidal
et al., 2004a). Intranuclear inclusions are large enough to almost
completely occupy the nucleus mechanically forcing chromatin
against the nuclear membrane. IBs can be seen as homogenous,
eosinophilic bodies, which can be labeled by antibodies against
FIGURE 2 | Inclusion bodies, iron deposits, and immunohistochemistry
from a patient with hereditary ferritinopathy. Sections of putamen show
numerous ferritin IBs of various sizes (A–E), which are ubiquitinated (E).
Ferritin IBs were also present in neurons and glial cells of the cerebellum
(F). Hematoxylin and eosin (A); Perls’ Prusian blue method for iron (B); and
immunohistochemistry using antibodies against mutant FTL (C), wild-type
FTL (D), ubiquitin (E), and FTH1 (F). Scale bars: (A–F), 50μm.
FTL and FTH1 polypeptides of ferritin and by antibodies specific
for the mutant FTL polypeptide. Inclusions also contain Fe2+ and
Fe3+, as determined by Turnbull blue and by Perls’ or Prussian
blue, respectively. By transmission electron microscopy (TEM),
nuclear IBs are seen as composed of small (∼100 Å) granular
electron-dense particles that resemble ferritin and occupy a large
portion of the nucleoplasm. IBs have been reported in the skin,
kidney, liver, and muscle in affected individuals from French and
American families (Vidal et al., 2004a; Mancuso et al., 2005). The
presence of ferritin IBs in skin or muscle biopsies may help in the
diagnosis of the disease.
FUNCTIONAL ABNORMALITIES IN MUTANT-CONTAINING
FERRITIN
The isolation and biochemical analysis of IBs from individu-
als with HF identified wild-type FTL, FTH1 and mutant FTL
polypeptides as the main components of IBs (Vidal et al., 2004a).
Although ferritin is generally isolated as a heteropolymer of
FTH1 and FTL subunits, initial structural and functional stud-
ies focused on the biological significance of the mutant as a
24-mer in its homopolymeric form. Thus, recombinant wild
type (WT)- andmutant (MT)-FTL (p.Phe167SerfsX26) polypep-
tides were separately expressed in E. coli, reconstituted with all
iron removed, and analyzed. Both polypeptides were soluble
and assembled as 24-mer homopolymers by size exclusion chro-
matography (SEC). TEM analysis showed that the ferritin particle
had a spherical shape and size (outer diameter ∼110Å) similar
to that of human ferritin (Baraibar et al., 2008). When WT-FTL
apoferritin homopolymers (1μM) were iron-loaded following a
routine procedure by aerobic incubation with up to 4500 iron
atoms per 24-mer of ferrous ammonium sulfate for 2 h, no
precipitation was found. However, precipitation of the Mt-FTL
homopolymer was observed to begin when the number of iron
atoms was higher than ∼1500 iron atoms per ferritin 24-mer. By
monitoring direct iron incorporation by native PAGE followed by
Prussian blue stain, it was observed that at moderate iron loading
of up to ∼1000 iron atoms per ferritin 24-mer and 2 h incuba-
tion, WT- and MT-apoferritin homopolymers incorporated very
similar amounts of iron, which implies a degree of functional-
ity for both. However, at higher iron to ferritin ratios, WT-FTL
homopolymers continued incorporating iron, whereas incorpo-
ration by MT-FTL homopolymers dropped precipitously. The
change in absorbance at 310 nm measured during the first 500 s
after mixing iron and ferritin in a 1000 to 1 ratio was substan-
tially larger for WT-FTL vs. MT-FTL homopolymers, uncovering
a clear difference in iron handling between mutant and wild type
ferritin at early times after mixing (Baraibar et al., 2010). When
in separate solutions, both WT- and MT-FTL homopolymers
showed significant ability to incorporate iron, but when in direct
competition (in the same solution), there was complete absence
of iron incorporation by MT-FTL. No precipitation was noted,
which highlights the importance of direct iron mishandling by
mutant ferritin without the effects of the iron-induced precip-
itation. The direct role of iron in the precipitation of MT-FTL
homopolymers was further emphasized by using the iron chela-
tor deferoxamine (DFX). Importantly, it was observed that greater
than 50% of mutant homopolymers that were precipitated by the
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addition of iron (3500 iron atoms per 24-mer) were re-solubilized
by incubation with DFX (Baraibar et al., 2008), highlighting
chelation as a major in vitro modulator of MT-FTL aggregation,
which is an important marker for HF in vivo.
These homopolymeric studies were followed by examina-
tion of ferritin heteropolymers reconstituted with an equal
number of mutant and wild type subunits in each 24-mer
(Muhoberac et al., 2011). The intermediate mobility on SDS-
PAGE and overlap in SEC profiles were indicative of appropriate
co-assembly. It was found that both forms of heterepolymers con-
taining theMT-FTL subunit (MT-FTL/FTH1,MT-FTL/WT-FTL)
and again MT-FTL homopolymers themselves were signifi-
cantly more susceptible to iron-loading induced precipitation
than either the WT-FTL/FTH1 heterepolymer or the WT-FTL
homopolymer, when analyzed by the same above-mentioned
routine procedure. Thus, reconstitution of mutant with either
wild type does not rescue ferritin from the iron-induced
aggregative behavior (Muhoberac et al., 2011). Furthermore,
a direct measure of iron incorporation using native PAGE
and Prussian blue stain showed that WT-FTL/FTH1 was
twice as capable of incorporating iron than MT-FTL/FTH1
heteropolymers. Importantly, some iron was still incorpo-
rated with mutant-containing ferritin suggesting some level of
functionality.
Recently, oxidation of MT-FTL was observed to occur both
in vitro and in vivo in individuals with HF (Baraibar et al.,
2012). Incubation of MT-FTL homopolymers with physiological
concentrations of iron and ascorbate resulted in shell structural
disruption and polypeptide cleavage not found under the same
conditions with WT-FTL. Along with the ∼21 kDa FTL polypep-
tide were found fragments of ∼ 6 and ∼14K Da, as well as one
of ∼27 kDa suggesting covalent crosslinking. Mutant ferritin also
underwent a 2.5-fold increase in carbonyl group formation over
wild type. Polypeptide cleavage and shell disruption was com-
pletely inhibited by addition of the radical trap 5,5-dimethyl-1-
pyrroline N-oxide, indicating an enhanced propensity of MT-FTL
24-mers toward free radical-induced, oxidative damage in vitro.
Importantly, IBs from a patient with HF exhibited extensive car-
bonylation together with an isolatable C-terminal MT-FTL frag-
ment of ∼14 kDa, which are both indicative of in vivo oxidative
ferritin damage. These data point toward a connection between
oxidative damage, mutant ferritin, and HF, and suggest that
radical scavengers (i.e., more generally antioxidants) and iron
chelators have the potential to be therapeutic agents for treatment
of HF.
E-HELIX DISRUPTION AND ENHANCED AGGREGATION IN
MUTANT-CONTAINING FERRITIN
The structure of the spherical protein shell is maintained in
mutant ferritin as was seen in the crystallographic structures of
the MT-FTL (p.Phe167SerfsX26) homopolymers (Baraibar et al.,
2010). However, a close up examination of the 4-fold pores
showed remarkable disruption of the MT-FTL C-terminal helices
making the pores unstable and leaky (Figure 3 vs. Figure 1D).
Because as many as the last 26 amino acids of MT-FTL remained
unaccounted for crystallographically, mutant C-termini may
extended and reach as far as the diameter of the ferritin shell
FIGURE 3 | Structural disruption of the 4-fold pores of ferritin caused
by the C-terminal mutation. Each wild type 4-fold pore is formed from
four tightly associated E-helices, one donated from each subunit, as seen in
Figure 1D. With the mutant, the E-helices are unraveled causing significant
disruption of the 4-fold pores and providing extended and disordered
C-termini, which are not visible by X-ray crystallography. This MT-FTL 4-fold
pore is an example of several, which vary somewhat in disruption details,
and is viewed from the ferritin shell interior. The structure was taken from
RCSB (code 3HX5).
itself. The C-terminal sequence of the mutant contains a number
of groups known to bind iron, e.g., the C-terminal carboxylate,
glutamate, tyrosinate and the hydroxyl groups of several serines
and threonines. Considering the sensitivity of ferritin-containing
MT-FTL to in vitro and in vivo (see below) iron-induced aggrega-
tion, a model was proposed in which iron binds to the unraveled
and extended mutant C-termini on two different ferritin shells
bridging them and initiating a gradual aggregation of ferritin
and iron into a precipitate (Figure 4). Bridging is not necessar-
ily restricted to C-termini and may become more general, e.g.,
between a C-terminal group and a surface amino acid which both
have affinity for iron (Baraibar et al., 2008, 2010). This model has
potential additional complexities because of (1) the very strong
dependence of the strength of iron binding to certain groups on
its redox state and (2) the existence of small iron hydroxide nucle-
ation centers that may form in solution without the presence
of protein.
The role of the mutant C-terminus and its protrusion above
the protein shell in the iron-induced aggregation process was
characterized further by comparing the iron loading of apo-
ferritin homopolymers composed of WT-FTL, MT-FTL and a
C-terminally truncated FTL polypeptide (p.S167X). The assem-
bly status of the truncated FTL polypeptide as a homopolymer
(24-mer) was verified by SEC and gel electrophoresis. In con-
trast to MT-FTL homopolymers, which began to precipitate at
∼1500 iron atoms per 24-mer, both the WT-FTL and truncated
FTL homopolymers remained in solution up to a ratio of 4000 to
1. Thus, removal of the mutant portion of the C-terminus pre-
vented iron-induced precipitation reinforcing the importance of
the interaction between iron and the disordered C-terminus in
the aggregation process (Baraibar et al., 2010).
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FIGURE 4 | Model of iron-induced aggregation of ferritin containing the
C-terminal mutation. Unraveled MT-FTL C-terminal E-helices (brown lines)
can extend a substantial distance from the ferritin shell surface into the
solvent providing a number of groups that can coordinate iron. Addition of
iron to a solution of MT-FTL-containing ferritin initiates bridging of C-termini
by iron (or iron nucleation complexes) reducing their translational motion.
Cross-linking may occur between two separate ferritin 24-mers through
iron bridges between C-termini (A), between a C-terminus and surface
iron-binding amino acid side chain (B), and/or eventually through surface
amino acids that bind iron on both 24-mers (C) forming ferritin aggregates
[adapted from Baraibar et al. (2008)].
IRON CHELATION AND RADICAL TRAPPING IN ANIMAL AND
CELLULAR MODELS OF HF
A transgenic animal model of HF (FTL-Tg) was generated in
order to increase our understanding of the effects of MT-FTL on
brain iron metabolism and ferritin expression and disposition.
A human FTL cDNA carrying a thymidine and cytidine inser-
tion at position 498 (c.497_498dupTC) was expressed in mouse,
leading to iron mishandling, ferritin accumulation, and oxida-
tive stress (Vidal et al., 2008). Expression of the transgene caused
the formation of nuclear and cytoplasmic ferritin IBs in glia and
neurons throughout the CNS (Figure 5), as well as in cells of
other organ systems. The size and number of nuclear inclusions
increased with age becoming large enough to cause mechanical
crowding and displacement of chromatin, as was found in HF
patients (Vidal et al., 2004a). FTL-Tg mice had a progressive neu-
rological phenotype, a significant decrease inmotor performance,
and a shorter lifespan. These mutant mice showed an increase in
brain iron and altered levels of associate proteins. Cytoplasmic
FTL and FTH1 polypeptides increased and the transferrin recep-
tor level decreased, as would be the expected in response to excess
iron. Ubiquinated proteins and portions of the proteosome (20S,
11S, and 19S) accumulated in the IBs, implying cellular recogni-
tion of the presence of abnormal protein aggregates. FTL-Tgmice
FIGURE 5 | Inclusion bodies and immunohistochemistry from a
transgenic mouse model of hereditary ferritinopathy. Sections of
cerebral cortex (A), globus pallidus (B), and cerebellum (C) of FTL-Tg mice
show the presence of numerous ferritin IBs. Sections were from a 9 month
old homozygous male (A,B) and an 11 month old heterozygous male (C).
Immunohistochemistry was performed using antibodies against the
N-terminus of wild-type and mutant FTL (A–C). Scale bars: (A–C), 50μm.
showed accumulation of oxidative DNA damage in brain mito-
chondria, but no significant damage to nuclear DNA (Deng et al.,
2010). Furthermore, markers for oxidative stress such as protein
carbonyl formation, nitrone-protein adducts, and lipid peroxida-
tion, were found in the brain indicative of cellular damage by ROS
(Barbeito et al., 2009).
Ferritin levels in primary cultures of astrocytes from the
cerebral cortex of FTL-Tg mice respond dramatically to expo-
sure to iron and chelators. Cell treatment with 50 uM ferric
ammonium citrate (FAC) caused a switch of MT-FTL ferritin
from the detergent-soluble to the detergent-insoluble fraction,
strongly supporting a role for iron in the formation of IBs.
After removal of FAC solution, addition of 50 uM of the
lipophilic iron chelator 1,10-phenanthroline to the FAC-treated
cells led to a large reduction in detergent-insoluble ferritin and
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the reappearance of ferritin in the detergent-soluble fraction.
Phenanthroline is a freely cell-permeable chelator and was chosen
for the study over the weakly cell-permeable chelator deferroxam-
ine (Baraibar et al., 2008). These studies show that IB formation
is strongly dependent on iron levels and can be reversed by
using iron chelators in vivo, which supports chelation therapy
as a potential treatment to inhibit aggregation and reduce IB
formation in HF.
Primary cultures of human skin fibroblasts from patients with
HF were also used to characterize the effects of MT-FTL on
cellular iron metabolism (Barbeito et al., 2010). These cells exhib-
ited iron mishandling, ferritin accumulation, and evidence of
oxidative stress, paralleling the dysfunction seen in both patients
with HF and the mouse model. Mutant fibroblasts showed a sig-
nificant increase in the level of total iron content under basal
metabolic conditions when compared to wild type fibroblasts,
but interestingly, without a significant difference in the level of
the liable iron pool, which is the iron more readily available
for metabolism. Cellular levels of MT-FTL, WT-FTL, and FTH1
polypeptides were all substantially increased in HF vs. wild type
fibroblasts. IRE-IRP binding was reduced in HF fibroblasts con-
sistent with the observed enhanced ferritin and decreased trans-
ferrin receptor-1 synthesis, and broadly consistent with higher
total iron levels in HF fibroblasts. Significant higher levels of ROS
were found in HF vs. non-HF fibroblasts (Barbeito et al., 2010),
which supports antioxidant therapy as a potential treatment
for HF.
ABNORMAL FERRITIN FUNCTION CAUSED BY THE MUTANT
POLYPEPTIDE
Hereditary ferritinopathy provides a direct link between abnor-
mal iron homeostasis and neurodegeneration. The pronounced
cellular dysfunction in the pathogenesis of HF centers on three
observable and well-characterized cellular abnormalities - iron
accumulation, IB formation, and protein oxidation - as described
in this review. All of these abnormalities involve a specific
molecular-level defect of the MT-FTL C-terminal sequence caus-
ing (1) 4-fold pore disruption with reduced ability to store
and sequester iron, and (2) unraveling and extension of the
C-terminus causing iron-induced aggregation of ferritin. Both (1)
and (2) contribute to increasing iron levels leading to the misdi-
rected cellular response of synthesis of more ferritin to sequester
iron, which in turn, creates a destructive positive feedback loop
that accumulates ferritin and taxes cellular resources. Handling
increasing levels of improperly sequestered and stored iron is
problematic. Improperly ligated iron, whether this occurs on
smaller ferritin aggregates, in IBs, or even through coordination
by small molecule cellular constituents, produces ROS leading to
protein oxidation, as is evident in the in vitro and in vivo studies
reviewed here. Increasing levels of iron also enhance the aggre-
gation of MT-FTL-containing ferritin, further exacerbating the
situation. IBs contain both Fe2+ and Fe3+, which suggests that
ROS could be generated within them. Although HF is an auto-
somal dominant disease, the age at onset of the disease is not
in early childhood, suggesting that the cells are apparently able
to handle the many insults initially, but later succumb to cumu-
lative damage. Taken together, a working hypothesis (Figure 6)
for the role of MT-FTL in the pathogenesis of HF consistent
with the results presented here implies both (1) a loss of nor-
mal ferritin function (decreased iron incorporation) that triggers
intracellular iron accumulation and overproduction of ferritin
polypeptides, and (2) gain of toxic function through radical pro-
duction, ferritin aggregation, and oxidative stress. The concept
of loss of normal function and gain of toxic function may have
applicability to the understanding of other disease processes,
especially when considering interactions with transition metal
ions and available cellular reductants. More generally, a protein
mutation or conformational change that leads to loss of nor-
mal function may also allow the ligation of transition metals
to abnormal protein binding sites with the two major conse-
quences of ROS generation and protein aggregation, which are
both a gain of toxic function. It should be noted that zinc,
although not redox active, can induce substantial protein aggre-
gation, and may thus play an important role (Ayton et al., 2012).
The loss of normal function could lead to a positive feedback
loop in compensating cellular protein synthesis producing more
abnormal protein metal binding sites, and could be further com-
plicated if the protein in question normally handles transition
metal ion transport or removal. It is somewhat ironic that the
major iron storage protein ferritin acquires through mutation
both the inability to properly handle iron and an enhanced
aggregative sensitivity toward the metal that it is designed to keep
in homeostasis.
OUTLOOK FOR TREATMENT
Currently there is no effective treatment for HF. Therapies aimed
at decreasing iron levels or inhibiting ferritin synthesis would
appear to be indicated in view of the pivotal roles played by
ferritin and iron in cellular metabolism. Decreasing iron levels
toward normal or eliminating mutant FTL polypeptide synthe-
sis in HF patients by the more direct approach of gene therapy
using viral transfer and expression that could influence iron or
ferritin levels would be time consuming, costly to develop, and
with some uncertainty of efficacy. Decreasing iron levels toward
normal with appropriately designed chelators would reduce ROS
production, pathological iron-induced aggregation, and IB for-
mation. However, use of the iron chelators desferrioxamine and
deferiprone (as well as venesection) was reported to cause pro-
found and refractory iron depletion without clinical benefits
(Chinnery et al., 2007). Although this initially may sound dis-
couraging, the relatively limited number and variety of chelators
examined until now as treatment for HF patients should be care-
fully considered. Chelators are characterized by a large number
of molecular properties that need to be optimized to match both
the complexities of the cellular system and the disease being
treated. The choice of a chelator (and in the longer term its
discovery and design) is difficult because optimization of one par-
ticularly molecular property to the cellular system and disease
may adversely affect the optimization of another. For example,
adding a particular group to the skeleton of a chelator to opti-
mize lipid- vs. aqueous-solubility may adversely affect its redox
properties or binding strength. Indeed, there are a number of
considerations to chelator efficacy beyond facile blood-brain bar-
rier penetration and increasing the binding strength as follows:
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FIGURE 6 | Interrelationship between iron accumulation, ROS
generation, inclusion body formation, and neurodegeneration in
hereditary ferritinopathy. The pathogenesis of HF is consistent with (1) a
loss of normal ferritin function through a decrease in iron incorporation into
ferritin that triggers intracellular iron accumulation and overproduction of
ferritin polypeptides (a positive feedback loop) and (2) a gain of toxic function
through radical production, ferritin aggregation, and oxidative stress. ROS can
form at improperly ligate iron bound to small ferritin aggregates and IBs, as
well as to other cellular constituents (e.g., small molecules) because of
elevated iron as represented by the lowest curved arrow in figure. The most
toxic ROS is the hydroxyl radical that indiscriminately attack proteins, lipids
and DNA causing extensive cellular damage.
(1) The chelator must selectively bind and release iron and not
interfere significantly with the concentration, transport, and dis-
tribution of other metals. (2) Iron binding and removal must
occur in a manner as not to sequester iron from function-
ing enzymes that require it for activity. (3) The chelator and
iron-chelator complex must be hydrophobic enough to perme-
ate multiple membrane barriers to redistribute iron for eventual
excretion. (4) The iron-chelator complex should have redox and
coordination properties such that it does not itself serve as a
source of ROS using available oxygen and reducing equivalents in
the brain. This list of considerations and the fine tuning of chela-
tor molecular properties that it implies stand in contrast to the
two chelators already explored to treat HF both in number and
molecular composition. More generally this list is in contrast to
the few chelators currently approved by the FDA for iron-overload
therapy implying that chelation therapy for HF remains mainly
unexplored.
Although additional in vitro characterization of mutant
ferritin in combination with computational approaches may
eventually prove useful in defining compounds with opti-
mal molecular properties for drug candidates for HF therapy,
it is important to consider application of currently available
in vivo approaches employing existing animal and cellular mod-
els. One approach would be to develop a screening proce-
dure using fibroblasts or astrocytes from HF patients against
a small molecule library akin to the NIH Molecular Libraries
Program or other similar programs. Whole animal studies using
the mouse model would follow. In the best case scenario, the
drug candidates would be the same or similar to an approved
FDA drug. A more focused approach would perhaps be to
screen approved drugs known to have iron deficiency as a side
effect.
Although the preceding discussion targets the ability of chela-
tors to remove and redistribute iron and to resolubilize or
prevent ferritin aggregation, as was demonstrated to be oper-
ational both in vitro and in vivo by examples in this review,
inhibition of oxidative damage by a free radical scavenger was
also described. Damage by ROS could be reduced by removal
of excess iron, but could also be reduced by the presence of
radical scavengers. This points to the investigation of com-
bined drug therapy for HF patients in the form of adminis-
tering an optimal iron chelator simultaneously with a power-
ful antioxidant known to easily cross the blood brain barrier.
The combined therapy as outlined here, especially if initiated
early, may be more successful, not only for HF, but also for
other neurodegenerative diseases characterized by brain iron
deposition.
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